Could AbbVie’s New Collaboration Be a Blockbuster?

Earlier this month, AbbVie ( NYSE:ABBV ) announced a deal with biotechnology company Regenxbio ( NASDAQ:RGNX ) to treat eye disorders using gene therapy. Specifically, the two companies are collaborating to develop and commercialize a gene therapy candidate, RGX-314, which is currently in phase 2 clinical trials. Let’s take a deeper look at this agreement, and the potential revenue it could generate for AbbVie.

Read the source article at Fool.com
2021-09-27 11:45:00